Full-Time

Patent Counsel

Posted on 8/29/2024

Vir Biotechnology

Vir Biotechnology

501-1,000 employees

Develops monoclonal antibodies for infectious diseases

Compensation Overview

$242k - $329.5k/yr

+ Bonus + Equity

Expert

San Francisco, CA, USA

This is an on-site position in our San Francisco Headquarters.

Category
Intellectual Property (IP)
Legal & Compliance
Requirements
  • A Juris Doctorate and admission before a State Bar or qualified legal credentials in geography of operations.
  • Minimum 13 years of industry and/or law firm experience.
  • Experience building trust with the legal teams and functional partners across the company.
  • Experience working both on individual projects and projects requiring a high degree of collaboration.
  • An understanding of genetic, protein, antibody, and recombinant technologies.
  • Experience in the biotechnology, immunology, or pharmaceutical industries.
  • Degree in Molecular Biology, Biochemistry, Biology, Chemistry, Cell Biology, Immunology, Life Science, pharmaceutical or related sciences.
Responsibilities
  • Develop and implement patent portfolio worldwide.
  • Review invention disclosures and create filing strategy.
  • Prosecute US and international patent applications.
  • Draft and review documents for oppositions, observations, and other patent office proceedings.
  • Conduct patentability and freedom-to-operate assessments, provide legal opinions and consultation.
  • Be the main IP representative to assigned projects and make preliminary recommendations to management.
  • Work with external collaborators and support in-licensed patent portfolios.
  • Collaborate with cross-functional teams and manage outside counsel.
  • Develop and maintain a detailed understanding of assigned projects.
  • Participate in the drafting and negotiation of agreements relating to intellectual property rights.
  • Provide IP support and due diligence review for business development activities.
  • Review proposed publications and external disclosures.
  • Participate in development of internal processes and training materials relating to IP.
  • Provide high quality, practical legal advice, and identify and resolve critical legal and business issues arising from all areas of the organization.
  • Foster collaborative relationships with a diverse set of partners across global sites and at all levels of the organization, and create efficient processes for communicating, advising, and working with those partners.
  • Cultivate a culture that reflects a commitment to diversity, inclusion, and community as part of an organization focused on bringing new insights and novel therapeutic options to patients worldwide.

Vir Biotechnology develops treatments for infectious diseases by leveraging the immune system. They use a proprietary monoclonal antibody platform combined with machine learning to create a database of human antibodies, which helps in designing effective medicines. Their pipeline includes candidates for hepatitis B, HIV, and various viruses like influenza and COVID-19. Vir stands out through its collaborations with industry leaders and its commitment to addressing unmet medical needs.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased AI-driven drug discovery partnerships enhance Vir's therapy development capabilities.
  • Growing demand for monoclonal antibodies aligns with Vir's expertise, opening new market opportunities.
  • Global pandemic preparedness push provides financial and strategic benefits to Vir.

What critics are saying

  • Leadership instability due to key executive resignations may disrupt strategic direction.
  • Job cuts and facility shutdowns could lead to operational challenges and impact morale.
  • Struggles to build on COVID-19 success indicate potential difficulties in maintaining market position.

What makes Vir Biotechnology unique

  • Vir uses AI-enhanced capabilities to engineer a rich database of human antibodies.
  • The company combines immunologic insights with cutting-edge technologies for infectious disease treatment.
  • Vir's proprietary monoclonal antibody platform targets diseases with significant global burden.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive healthcare coverage

Employer matched 401(k)

Employee stock purchase plan

Childcare assistance

Tuition reimbursement

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

1%
U.S. Securities and Exchange Commission
Dec 5th, 2024
vir-10q_20200331.htm

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Investing.com
Aug 1st, 2024
Vir Biotechnology inks major deal with Sanofi unit

Moreover, Vir Biotechnology has entered into a significant licensing agreement with Amunix Pharmaceuticals, Inc., a Sanofi company.

MarketScreener
Aug 1st, 2024
Vir Biotechnology to Cut 140 Jobs in Restructuring to Focus on Hepatitis Drug Development

Vir Biotechnology to cut 140 jobs in restructuring to focus on hepatitis drug development.

Simply Wall St
May 5th, 2024
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

Vir Biotechnology, Inc. (NASDAQ:VIR) just released its quarterly report and things are looking bullish.

Investing.com
Apr 18th, 2024
Vir Biotechnology CFO Sung Lee to step down in May

Vir Biotechnology Inc. (NASDAQ:VIR) announced Monday that Executive Vice President and Chief Financial Officer Sung Lee will resign from his position effective May 3, 2024.

INACTIVE